Biofrontera Inc. 10-Q

Item 5. Other Information None 34 Item 6. Exhibits The following exhibits are filed herewith or are incorporated by reference to exhibits previously filed with the SEC. Exhibit No. 4.1 Form of Common Stock Purchase Warrant issued in connection with the private placement on May 17, 2022 (the “May 2022 PIPE”) (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on May 20, 2022). 4.2 Form of Pre-Funded Common Stock Purchase Warrant issued in connection with the May 2022 PIPE (incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K filed with the SEC on May 20, 2022). 10.1† Amendment to Employment Agreement effective as of April 1, 2022 – Erica Monaco (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on April 5, 2022). 10.2# Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on May 20, 2022). 10.3 Form of Registration Rights Agreement for May 2022 PIPE (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on May 20, 2022). 31.1* Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002 32.1* Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002 101.INS* Inline XBRL Instance Document 101.SCH* Inline XBRL Taxonomy Extension Schema Document 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101) * Filed herewith. † Indicates a management contract or compensatory plan or arrangement. # The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of Regulation S-K. The registrant agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the SEC upon request. 35 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BIOFRONTERA INC. Date: August 12, 2022 By: /s/ Erica Monaco Name: Erica Monaco Title: Chief Executive Officer ( Duly Authorized Officer, Principal Executive Officer and Principal Financial Officer ) 36